NCT00295230 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Abubakar K, Keszler M
Effect of volume guarantee combined with assist/control vs synchronized intermittent mandatory ventilation. J Perinatol. 2005 Oct;25(10):638-42.
Cheema IU, Ahluwalia JS
Feasibility of tidal volume-guided ventilation in newborn infants: a randomized, crossover trial using the volume guarantee modality. Pediatrics. 2001 Jun;107(6):1323-8.
Herrera CM, Gerhardt T, Claure N, Everett R, Musante G, Thomas C, Bancalari E
Effects of volume-guaranteed synchronized intermittent mandatory ventilation in preterm infants recovering from respiratory failure. Pediatrics. 2002 Sep;110(3):529-33.
Keszler M, Abubakar K
Volume guarantee: stability of tidal volume and incidence of hypocarbia. Pediatr Pulmonol. 2004 Sep;38(3):240-5.
Mrozek JD, Bendel-Stenzel EM, Meyers PA, Bing DR, Connett JE, Mammel MC
Randomized controlled trial of volume-targeted synchronized ventilation and conventional intermittent mandatory ventilation following initial exogenous surfactant therapy. Pediatr Pulmonol. 2000 Jan;29(1):11-8.

The Effects of Volume Guarantee Combined With Pressure Supported Ventilation (PSV+VG) Versus Synchronized Intermittent Mandatory Ventilation (SIMV+VG) in Very Low Birth Weight Infants

Details for clinical trial NCT00295230

Clinical trial NCT00295230 - References